Cellebrite DI Ltd. (NASDAQ:CLBT) Given Average Rating of “Moderate Buy” by Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $21.75.

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cellebrite DI in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Finally, Lake Street Capital lowered their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 15th.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $19.56 on Thursday. The company’s fifty day moving average price is $16.83 and its 200 day moving average price is $16.92. Cellebrite DI has a 1 year low of $13.10 and a 1 year high of $26.30. The stock has a market capitalization of $4.68 billion, a P/E ratio of -25.74, a P/E/G ratio of 3.47 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm had revenue of $113.28 million for the quarter, compared to analysts’ expectations of $112.33 million. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Voss Capital LP boosted its position in shares of Cellebrite DI by 34.0% during the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after acquiring an additional 1,306,398 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Cellebrite DI by 17.1% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after acquiring an additional 570,000 shares during the last quarter. Invesco Ltd. boosted its position in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after acquiring an additional 209,473 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in shares of Cellebrite DI during the 1st quarter valued at about $60,939,000. Finally, Pertento Partners LLP boosted its position in shares of Cellebrite DI by 11.8% during the 2nd quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after acquiring an additional 309,988 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.